Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.

Publisher Website
Google Scholar
Abstract
There is no evidence that combination chemotherapy is superior to single agents in the treatment of advanced, hormone-resistant carcinoma of the prostate. Reported are the preliminary results of a randomized trial comparing cyclophosphamide (CTX) with a combination of 5-fluorouracil, doxorubicin and mitomycin C (FAM''). Thirty-one patients were randomized, and 30 of them were evaluable for response. Sixteen patients were treated with CTX, and 14 with FAM''. On the CTX arm, 8 (50%) of the patients had stable disease (SD) and 8 (50%) had progressive disease (PD). On the FAM'' arm, 1 (7%) patient had partial response (PR), 5 (36%) patients had SD and 8 (57%) failed to respond. The difference in response rates between the 2 regimens was not significant (P > 0.72). The median time to progression (MTP) of all patients treated with CTX was 6 wk, and the MTP of patients treated with FAM'' was 16 wk (P < 0.007). This difference in MTP could be explained in part by the unequal time to reevaluation between the 2 regimens. The MTP of the responders on CTX was 13 wk, while for FAM'' it was 33 wk (P = 0.014). This difference suggests that FAM'' has superior activity to CTX. Pain alleviation was seen in 25% of patients treated with CTX and in 64% of those treated with FAM'' (P < 0.01). Toxicity was tolerable on both regimens. Apparently, CTX and FAM'' have similar response rates. Patients treated with FAM'' enjoyed longer MTP and greater pain alleviation than those treated with CTX.

This publication has 1 reference indexed in Scilit: